Treatment of New World cutaneous leishmaniasis with miltefosine
about
sameAs
Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopyThe Cure Rate after Placebo or No Therapy in American Cutaneous Leishmaniasis: A Systematic Review and Meta-AnalysisA Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment OutcomeAntiparasitic therapyTamoxifen is effective in the treatment of Leishmania amazonensis infections in miceIn vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasitesDirect comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasisPhospholipid and sphingolipid metabolism in Leishmania.A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis.Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.In vitro and in vivo studies of the utility of dimethyl and diethyl carbaporphyrin ketals in treatment of cutaneous leishmaniasis.In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up.Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasisKinetoplastids: related protozoan pathogens, different diseases.Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistanceTreatment of cutaneous leishmaniasis in travelers 2009.Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis.Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis.Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art.Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis.Chemotherapy of leishmaniasis: present challenges.Preclinical drug evaluation system in the Plasmodium knowlesi baboon model of malaria: the methotrexate study.Interactions of antiparasitic alkaloids with Leishmania protein targets: a molecular docking analysis.American cutaneous leishmaniasis in infancy and childhood.Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.The effect of (-)-epigallocatechin 3-O--gallate in vitro and in vivo in Leishmania braziliensis: involvement of reactive oxygen species as a mechanism of action.Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug.In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis.Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most.
P2860
Q24615049-7E5ECFFD-A96E-4325-86EB-FE8E6286F9F1Q26764752-9E57970F-C518-44EC-8289-0A704327CE1FQ27303693-ABEAE1F2-1742-4453-AE18-5B0CD0244EE6Q28239164-94EFE47C-0854-452C-8BA3-1ECD4C0F0133Q28472920-65E152AD-8E20-4A3C-A122-1531D0D68825Q28482212-C5787C5B-2B19-4DF3-9CD9-9187783EC5A1Q28542936-1931B29F-F2CF-4652-A2B6-C236CF9AC83CQ33625755-860804E2-C5F8-45FA-A351-5D74E6856F66Q34422191-64C0C6EA-D4F5-4CFD-B00B-2CE99C22E17FQ34531216-2D0EB440-2E64-429D-8A50-92DFC99F2DC8Q35270608-86BF0BE6-0D02-41FE-A135-8B585D995249Q35840802-237495EC-8518-4700-82E9-8C41B6B9E3CDQ36077737-1BB60F63-1E05-4382-8E08-146E88D8A5AEQ36232091-BD8CB44B-C25E-4DF8-B598-AEBA7ED39ADEQ36513308-0DCA72C4-DF09-4C9C-A450-1B2F9E408A1EQ36899150-BDCB3FEA-C039-4623-97B8-F9BDDE7E5091Q37428084-D43E9FEE-6CC4-49F8-9CF1-19F76DC86DEAQ37450724-DB933D72-20FE-4C8A-AE3F-261CDB911B07Q38136837-BC002A64-6D88-4A95-AA33-D2C23F9BD6DAQ38156421-663F0508-DBD6-413F-98FA-C905AC396184Q38205451-D08F2469-22B2-4494-A8B3-2EF039274DADQ38458645-2086DC4A-043B-42BA-8457-EFEA1FCEA0E3Q38668340-D3999117-AD5E-4C0D-8375-8E88CC9E7C4CQ38939544-435F6DFA-C113-455D-A049-ABB7B357CB53Q38995293-F98286AC-03E6-4F32-B23A-B94CACBFC14CQ39011875-3FCF11C4-6C68-4262-9404-3A3B488D307DQ39092348-2A7BF67F-158B-4A52-90DF-E833720EDED7Q39328997-525577CD-5687-4235-BB89-43F0C8BC994FQ39336818-81A57343-375B-4569-BC63-AB46AC7B5D79Q40802236-ED0C2906-A337-440E-B93A-587E7E78C471Q42829637-C40F039A-80BB-4789-9A90-74CAD121AEE7Q43113859-4B315ED5-2F76-41EA-B3FF-BB813E05E40FQ46867851-1136488B-A72F-4644-89C5-FBA85A159A19Q54961274-EB26D2E6-B723-459E-B425-880D7395A23D
P2860
Treatment of New World cutaneous leishmaniasis with miltefosine
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Treatment of New World cutaneous leishmaniasis with miltefosine
@ast
Treatment of New World cutaneous leishmaniasis with miltefosine
@en
Treatment of New World cutaneous leishmaniasis with miltefosine
@nl
type
label
Treatment of New World cutaneous leishmaniasis with miltefosine
@ast
Treatment of New World cutaneous leishmaniasis with miltefosine
@en
Treatment of New World cutaneous leishmaniasis with miltefosine
@nl
prefLabel
Treatment of New World cutaneous leishmaniasis with miltefosine
@ast
Treatment of New World cutaneous leishmaniasis with miltefosine
@en
Treatment of New World cutaneous leishmaniasis with miltefosine
@nl
P2093
P2860
P3181
P1476
Treatment of New World cutaneous leishmaniasis with miltefosine
@en
P2093
P2860
P3181
P356
10.1016/J.TRSTMH.2006.02.022
P407
P577
2006-12-01T00:00:00Z